文献速递胸部肿瘤

COMPASS研究:晚期非鳞非小细胞肺癌持续维持治疗中贝伐珠单抗联合或不联合培美曲塞的随机III期研究

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
PubMed 文献 · J Clin Oncol · 2019-12-27

COMPASS研究评估晚期非鳞非小细胞肺癌患者经卡铂+培美曲塞+贝伐珠单抗诱导后,采用培美曲塞联合贝伐珠单抗对比单用贝伐珠单抗维持治疗的疗效与安全性。主要终点总生存无统计学显著获益,但培美曲塞联合贝伐珠单抗组无进展生存期延长,且在EGFR野生型亚组中总生存获益。

要点

  • 培美曲塞联合贝伐珠单抗维持治疗较单用贝伐珠单抗延长无进展生存期(5.7 vs 4.0个月)。

核心结论

  • 主要终点总生存未观察到统计学显著获益,但无进展生存期在总人群延长,EGFR野生型亚组总生存延长。

研究设计与样本

  • 随机III期研究,入组未经治疗且无EGFR 19缺失或L858R突变的晚期非鳞非小细胞肺癌患者。
  • 诱导治疗为卡铂AUC 6、培美曲塞500 mg/m2、贝伐珠单抗15 mg/kg,每3周一次,共4周期。
  • 诱导后无疾病进展者按1:1随机接受培美曲塞500 mg/m2联合贝伐珠单抗15 mg/kg或单用贝伐珠单抗15 mg/kg维持治疗,每3周一次。
  • 2010年9月至2015年9月,907例接受诱导治疗,599例随机分组:联合组298例,单药组301例。

主要发现

  • 安全性数据与既往治疗方案报告一致。

临床怎么用

  • 对于晚期非鳞非小细胞肺癌经含铂联合贝伐珠单抗诱导后无进展者,可考虑培美曲塞联合贝伐珠单抗持续维持治疗以延长无进展生存期。
  • EGFR野生型患者可能从培美曲塞联合贝伐珠单抗维持治疗中获得总生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with non-small-cell lung cancer (NSCLC) have been shown to benefit from maintenance therapy. COMPASS evaluated the efficacy and safety of bevacizumab with or without pemetrexed as continuation maintenance therapy after carboplatin, pemetrexed, and bevacizumab induction therapy. PATIENTS AND METHODS: Patients with untreated advanced nonsquamous NSCLC without confirmed EGFR 19 deletion or L858R mutation received first-line therapy with carboplatin area under the curve 6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg once every 3 weeks for 4 cycles. Patients without disease progression during the induction therapy were randomly assigned 1:1 for maintenance therapy with pemetrexed 500 mg/m2 plus bevacizumab 15 mg/kg or bevacizumab 15 mg/kg once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was overall survival (OS) after random assignment. RESULTS: Between September 2010 and September 2015, 907 patients received induction therapy. Of those, 599 were randomly assigned: 298 received pemetrexed plus bevacizumab, and 301 received bevacizumab. The median OS was 23.3 v 19.6 months (hazard ratio [HR], 0.87; 95% CI, 0.73 to 1.05; 1-sided stratified log-rank P = .069). In the wild-type EGFR subset, the OS HR was 0.82 (95% CI, 0.68 to 0.99; 1-sided unstratified log-rank P = .020). The median progression-free survival (PFS) was 5.7 v 4.0 months (HR, 0.67; 95% CI, 0.57 to 0.79; 2-sided log-rank P < .001). The safety data were consistent with previous reports of treatment regimens. CONCLUSION: In terms of the primary end point of OS, no statistically significant benefit was observed; however, PFS in the total patient population and OS in patients with wild-type EGFR was prolonged with the addition of pemetrexed to bevacizumab maintenance therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Seto T, Azuma K, Yamanaka T, et al. Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). J Clin Oncol. 2019. PMID: 31880966. doi:10.1200/JCO.19.01494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。